Physician profile
Allan Herskowitz
NPI 1134197981
$34,092.30
in general payments reported to CMS, 2019-2025
64 companies · $2,132 in 2025
The $2,132 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,626 · 2020: $17K · 2021: $5,173 · 2022: $2,312 · 2023: $3,024 · 2024: $3,009 · 2025: $2,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,165.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $17,474.79 | 2019-2022 | |
| Ucb, INC. | $3,508.25 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Abbvie INC. | $2,712.77 | 2021-2025 | |
| Amgen INC. | $1,504.83 | 2019-2025 | Uplizna, Aimovig |
| Novartis Pharmaceuticals Corporation | $781.20 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $553.81 | 2019-2024 | Austedo Xr, Austedo |
| Adamas Pharmaceuticals, INC. | $540.56 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $522.50 | 2020-2024 | Ingrezza, Ongentys |
| Lilly USA, LLC | $515.83 | 2019-2025 | Amyvid, Kisunla, Zepbound |
| Eisai INC. | $448.79 | 2019-2025 | |
| Pfizer INC. | $388.29 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $294.91 | 2020-2025 | Acthar |
| Neurelis, INC. | $274.96 | 2020-2025 | Valtoco |
| Acorda Therapeutics, INC | $268.75 | 2019-2023 | Inbrija |
| Harmony Biosciences LLC | $255.49 | 2020-2025 | Wakix |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Herskowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.